Circadian Rhythm Target Identified for Prostate Cancer

Laboratory studies by researchers at the Sidney Kimmel Cancer-Jefferson Health (SKCC) have found an unexpected role for the circadian clock gene CRY1, in prostate cancer progression. They say their findings identify CRY1 as pro-tumorigenic, and indicate that the protein could represent a new therapeutic target for the disease. The investigators say their findings also “open up a multitude of important research questions exploring the link between the circadian clock and cancer.”